中年成人CKD筛查的长期成本效益
本研究基于芬兰55岁人群构建终身Markov模型,比较一次eGFR/UACR筛查后对阳性者给予SGLT2i与RAASi治疗与不筛查的成本效益。
要点
- 55岁人群一次CKD筛查联合SGLT2i与RAASi治疗可改善长期结局。
- 筛查减少急性肾功能下降、心衰住院日、透析与移植暴露。
核心结论
- 在芬兰55岁人群中,一次eGFR/UACR筛查后对阳性CKD者给予SGLT2i与RAASi治疗可改善长期结局并可能具有成本效益。
研究设计与样本
- 采用队列Markov模型模拟芬兰55岁队列终身CKD进展。
- 比较当前实践(不筛查)与一次筛查后随访并对筛查阳性CKD给予SGLT2i和RAASi治疗两种策略。
- 筛查阳性定义为eGFR <60 mL/min/1.73 m²和/或UACR ≥3 mg/mmol,且≥3个月后重复样本确认慢性ity。
主要发现
- 筛查降低急性肾功能下降(0.88 vs 0.90事件/人)、心衰住院日(6.47 vs 6.69天/人)、透析暴露(0.29 vs 0.32患者年/人)和移植暴露(0.13 vs 0.14患者年/人)。
关键数值与推荐
- 筛查阳性标准:eGFR <60 mL/min/1.73 m²和/或UACR ≥3 mg/mmol,≥3个月后重复确认。
- 筛查阳性CKD者接受SGLT2i联合RAASi治疗。
- 模型涵盖CKD G1-G5、透析、移植和死亡所有阶段。
临床怎么用
- 在55岁人群中可考虑一次eGFR/UACR筛查以识别未诊断的早期CKD。
- 对筛查发现的CKD患者应在RAASi基础上联合SGLT2i以延缓进展并减少心肾事件。
局限性
- 原文未报告模型局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND HYPOTHESIS: Chronic kidney disease (CKD) is common in Finland and frequently remains undiagnosed until advanced stages. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) slow CKD progression and reduce cardio-renal events when used in addition to Renin-Angiotensin-Aldosterone System inhibitor (RAASi) treatment. We hypothesized that a one-time CKD screening program using measurements of estimated glomerular filtration rate (eGFR) and urine albumin-to-creatinine ratio (UACR), followed by SGLT2i and RAASi treatment for identified CKD, would be cost-effective in Finland. METHODS: We developed a cohort-based Markov model to simulate lifetime CKD progression in a Finnish cohort aged 55 years under two strategies: (1) current practice (no screening) and (2) one-time screening with follow-up and SGLT2i and RAASi treatment for screen-positive CKD (eGFR <60 mL/min/1.73 m² and/or UACR ≥3 mg/mmol; confirmed on a repeat sample after ≥ 3 months to establish chronicity). All CKD stages (G1-G5, dialysis, transplant, and death) were included in the model, and screening could detect CKD at any stage, although the incremental detection was concentrated in earlier, previously undiagnosed stages (G1-G3). Outcomes included discounted costs, quality-adjusted life years (QALYs), life years, and clinical outcomes (acute kidney function decline, heart-failure hospital days, dialysis and transplant patient-years, and deaths). Results are reported as means with 95% confidence intervals (CI). RESULTS: Screening increased discounted lifetime costs per person by €907 (95% CI €334-2 553) and QALYs by 0.14 (95% CI 0.07-0.31), yielding an incremental cost-effectiveness ratio of €6 478/QALY. Screening increased life years by 0.30. Screening reduced acute kidney function decline (0.88 vs 0.90 events/person), heart-failure hospital days (6.47 vs 6.69 days/person), dialysis exposure (0.29 vs 0.32 patient-years/person) and transplant exposure (0.13 vs 0.14 patient-years/person). CONCLUSIONS: In Finns aged 55 years, one-time CKD screening with eGFR/UACR followed by SGLT2i and RAASi treatment improves long-term outcomes and is likely cost-effective.
引用
- Jalkanen K, Aku-Ville L, Piia L, et al. Long-term cost-effectiveness of CKD screening in middle-aged adults. Nephrol Dial Transplant. 2026. PMID: 42925318. doi:10.1093/ndt/gfag252
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。